

23 July 2021

Via Email: [REDACTED]

### Response to a request for official information

Dear [REDACTED]

Thank you for your request for official information received 28 June 2021 by Nelson Marlborough Health (NMH)<sup>1</sup> where you seek the following information.

*Total number of patients with Crohn's disease of ulcerative colitis to receive biologic treatments (infliximab, adalimumab) between 2016 and 2020 inclusive who were;*

- 1. White New Zealander*
- 2. Maori*
- 3 Asian (Ideally separated into South Asian and East Asian)*
- 5. Pacific Islanders*

NMH response: Table One shows the number of patients with Crohn's disease of ulcerative colitis to receive biologic treatments (infliximab, adalimumab) between 2016 and 2020 (inclusive) who identify as one of the specified ethnic groups.

**TABLE ONE**

Ethnicity	Total
New Zealand European	93
Maori	8
Asian <i>not further defined</i>	1
Grand Total	102

This response has been provided under the Official Information Act 1982. You have the right to seek an investigation by the Ombudsman of this decision. Information about how to make a complaint is available at [www.ombudsman.parliament.nz](http://www.ombudsman.parliament.nz) or free phone 0800 802 602. If you have any questions about this decision please feel free to email our OIA Coordinator [OIArequest@nmdhb.govt.nz](mailto:OIArequest@nmdhb.govt.nz). I trust that this information meets your requirements. NMH, like other agencies across the state sector, supports the open disclosure of information to assist the public's understanding of how we are delivering publicly-funded healthcare. This includes the proactive publication of anonymised Official Information Act responses on our website from 10 working days after they have been released. If you feel that there are good reasons why your response should not be made publicly available, we will be happy to consider.

Yours sincerely



Lexie O'Shea  
**Chief Executive**

<sup>1</sup> Nelson Marlborough District Health Board